Hugo Linares, DO
Retina Specialist · Philadelphia, PANPI 1013143726
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,344 of the $6,530 with a category attached, or 66.5%. Regeneron accounts for 67.7% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $4,930, more than ten times the $319 reported in 2019.
Across 92 payments — averaging $70.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$4K
- Genentech USA, Inc.$495
- AbbVie$359
- Apellis Pharmaceuticals, Inc.$350
- Sandoz$206
- Regeneron Healthcare Solutions, Inc.$189
- plus $512 from 9 others
Across 8 payments — averaging $3931.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$31K
What the payments were for
- Consulting fees$4,34467%
- Food & beverage$2,10132%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 6 | $4,419 |
| Genentech USA, Inc. | 30 | $495 |
| AbbVie(2 entities) | 12 | $359 |
| Apellis Pharmaceuticals, Inc. | 10 | $350 |
| Sandoz | 6 | $206 |
| Regeneron Healthcare Solutions, Inc. | 10 | $189 |
| Coherus Oncology, Inc. | 3 | $117 |
| ANI Pharmaceuticals, Inc. | 3 | $91 |
| Alimera Sciences, Inc. | 4 | $85 |
| Dutch Ophthalmic, USA | 1 | $76 |
| Novartis | 3 | $51 |
| Samsara Vision | 1 | $34 |
| Neurotech Pharmaceuticals, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $15 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,530 in reported general payments places this provider in the 80th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $3,342 |
| Prednisolone Acetate | 70 | $3,014 |
| Ketorolac Tromethamine | 73 | $1,555 |
| Atropine Sulfate | 27 | $1,077 |
| ErythromycinErythromycin Base | 23 | $250 |
| Latanoprost | 20 | $237 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Philadelphia
- Joshua GreenePhiladelphia$394K
- Brian VanderbeekPhiladelphia$14K
- Albert MaguirePhiladelphia$9K
- Benjamin KimPhiladelphia$5K
- Tomas AlemanPhiladelphia$3K
- Robert CarrollPhiladelphia$1K
- Drew ScolesPhiladelphia$519
- Juan GrunwaldPhiladelphia$508
- Alexander BruckerPhiladelphia$86
- William FosterPhiladelphia$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.